Skip to main content
. 2018 Jan 30;25(1):376–387. doi: 10.1080/10717544.2018.1428242

Figure 5.

Figure 5.

Olfactory bulb to plasma ratio (OB/plasma ratio) after nasal administration of the same dose of ribavirin (1 mg) by intravenous injection (grey bar) or nasal administration of ribavirin agglomerates with α-cyclodextrin excipient microparticles (black bar) (n = 6, average ± SEM). Data for the intravenous administration are according to Colombo et al., 2011.